Bibliographie : Cannabinoïdes et Epilepsie

Bibliographie Cannabinoïdes et Epilepsie

Docteur Christian SUEUR, GRECC, septembre 2018.

 

  1. AGUIRRE-VELASQUEZ C.G. : Report from a Survey of Parents Regarding the Use of Cannabidiol (Medicinal cannabis) in Mexican Children with refractory Epilepsy, Hindawi, Neurology Research International, 2017, ID 2985729, 5 p.
  2. American Academy of Neurology : Medical marijuana liquid extract may bring hope for children with severe epilepsy, American Academy of Neurology Press, 2015.

https://www.aan.com/PressRoom/Home/PressRelease/1364

  1. AMES F.R., CRIDLAND S. : Anticonvulsivant effect of cannabidiol, South Africa Medical Journal, 1986, 69, 1, 14.
  2. ANDERSON P. : Positive Topline Results with Cannabidiol (Epidiolex) in Dravet Syndrome, medscape.com/viewarticle/860357_print, 2016
  3. BLAIR R.E., DESHPANDE L.S., De LORENZO R.J. : Cannabinoids : is there a potential treatment role in epilepsy ?, Expert Opin Pharmacother, 2015, 16, 13, 1911-1914.
  4. BLAIR R.E., DESHPANDE L.S., De LORENZO R.J. : Endocannabinoids and epilepsy, Chapter 6, Cannabinoids in Neurologic and Mental Disease, Academic Press, 2015, 125-172.
  5. BRIAN P.G., SCOTT C.B. : Animal models in epilepsy research : legacies and new directions, Nat Neurosciences, 2015, 18, 339-343.
  6. CARLINI E.A., CUNHA J.M. : Hypnotic and antiepileptic effects of cannabidiol, J Clin Pharmacol, 1981, 21, 417-427.
  7. CHEN K.A., FARRAR M., CARDAMONE M., GILL D. et al. : Cannabidiol for treating drug-resistant epilepsy in children: the New South Wales experience, Medical Journal of Australia, 2018 August 13.
  8. CHIU P., OLSEN D.M., BORYS H.K. et al : The influence of cannabidiol and delta 9-tetrahydrocannabinol on cobalt epilepsy in rats, Epilepsia, 1979, 20, 365-375.
  9. CILIO M.R., THIELE E.A., DEVINSKY O. : The case for assessing cannabidiol in epilepsy, Epilepsia, 2014, 55, 6, 787-790.
  10. CITRARO R., RUSSO E., De SARRO G. et al. : CB1 agonists, locally applied to the cortico-thalamic circuit of rats with genetic absence epilepsy, reduce epileptic manifestations, Epilepsy Research, 2013, 106, 1-2, 74-82.
  11. CONSROE P.F., WOOD G.C., BUCHSBAUM H. : Anticonvulsivant nature of marihuana smoking, JAMA, 1975, 234, 3, 306-307.
  12. CONSROE P.F., WOLKIN A. : Cannabidiol-antiepileptic drug comparisons and interactions in experimentally induced seizures in rats, J Pharmacol Exp Ther, 1977, 201, 1, 26-32.
  13. CONSROE P.F., MARTIN A., SINGH V. : Antiepileptic potential of cannabidiol analogs, J Clin Pharmacol, 1981, 21, 8-9, 428-436.
  14. CONSROE P.F. : Brain Cannabinoid systems as targets for the therapy of neurological disorders, Neurobiological Diseases, 1998, 5, 534-541.
  15. CUNHA J.M., CARLINI E.A., MECHOULAM R. et al. : Chronic administration of cannabidiol to healthy volunteers and epileptic patients, Pharmacology, 1980, 21, 3, 175-185.
  16. DETYNIECHI K., LAWRENCE H. : Marijuana use in epilepsy : the myth and the reality, Curr Neurol Neurosci Rep, 2015, 15, 65.
  17. DETYNIECKI K., HIRSCH L.J. : Cannabidiol for epilepsy : trying to see through the haze, The Lancet, 2016, 15, 3, 235-237.
  18. DEVINSKY O., VICKREY B.G., CRAMER J. et al. : Development of the quality of life in epilepsy inventory, Epilepsia, 1995, 36, 1089-1104.
  19. DEVINSKY O., CILIO M.R., Di MARZO V., FRIEDMAN D. et al. : Cannabidiol : pharmacology and potential therapeutic role in epilepsy and other neuropsychiatric disorders, Epilepsia, 2014, 55, 6, 791-802.
  20. DEVINSKY O. : Commentary : Medical Marijuana survey & Epilepsy, Epilepsia, 2015, 56, 1, 7-8.
  21. DEVINSKY O., MARSH E., FILLOUX F., BLUVSTEIN J., CILIO M.R. et al. : Cannabidiol in patients with treatment-resistant epilepsy : an open-label interventional trial, Lancet Neurology, 2015.
  22. DEVINSKY O., CROSS J.H., WRIGHT S. : Trial of Cannabidiol for Drug –Resistant Seizures in the Dravet Syndrome, New England Journal of Medicine, 2017, 376, 21, 2011-2020.
  23. Di MARZO V. : The endocannabinoid system : its general strategy of action, tools for its pharmacological manipulation and potential therapeutic exploitation, Pharmacological Research, 2009, 60, 2, 77-84.
  24. Dos SANTOS R.G., HALLAK J.E., LEITE J.P., ZUARDI A.W., CRIPPA J.A. : Phytocannabinoids and epilepsy, Journal of Clinical Pharm Ther, 2015, 40, 2, 135-143.
  25. EDWARDS M., PAIGE F. : The case for medical marijuana in epilepsy, Epilepsia, 2014, 55, 6, 783-786.
  26. ELLISON J.M., GELWAN E., OGLETREE J. : Complex partial seizure symptoms affected by marijuana abuse, Journal of Clinical Psychiatry, 1990, 51, 439-440.
  27. FEENEY D.M. : Marihuana Use Among Epileptics, JAMA, 1976, 235, 11, 1105.
  28. FEENEY D.M. : Marijuana and Epilepsy : paradoxical anticonvulsant effects, Advanced Biosciences, 1978, 22/23, 643-657.
  29. FEZZA F., MARRONE M.C., MACCARRONE M., MARINELLI S. : Distinct modulation of the endocannabinoid system upon Kainic Acid-induced invivo seizures and in vitro epileptiform bursting, Molecular and Cellular Neuroscience, 2014, 62, 1-9.
  30. FLOREK- LUSZCZKI M., ZAGAJA M, LUSZCZKI J.J. : Influence of WIN 55,212-2 on the anticonvulsant and acute neurotoxic potential of clobazam and lacosamide in the maximal electroshock- induced seizure model and chimney test in mice, Epilepsy Research, 2014, 108, 10, 1728-1733.
  31. FLOREK- LUSZCZKI M., ZAGAJA M, LUSZCZKI J.J. : Influence of arachidonyl-20-chloroethylamide, a selective cannabinoid CB1 receptor agonist, on the anticonvulsant and acute sid-effect potentials of clobazam, lacosamide, and pregabalin in the maximal electroshock-induced seizure model and chimney test in mice, Fundam Clin Pharmacol, 2015, 29, 382-393.
  32. FRIEDMAN D., CILIO M.R., TILTON N. et al. : The effects of Epidiolex (Cannabidiol) on serum levels of concomitant anti-epileptic drugs in children and young adults with treatment resistant epilepsy in an expand acess program, Annual Meeting of the American Epilepsy Society, Seattle, December 5-9, 2014, Abstract.
  33. FRIEDMAN D., DEVINSKY O. : Cannabinoids in the Treatment of Epilepsy, New England Journal of Medicine, 2015, 373, 1048-1058.
  34. GORDON E., DEVINSKY O. : Alcohol and Marijuana : Effects on Epilepsy and Use by Patients, Epilepsia, 2001, 42, 10, 1266-1272.
  35. GLOSS D., VICKREY B. : Cannabinoids for epilepsy, Cochrane Database Systematic Review, 2012, 6.
  36. GOFSHTEYN J.S., WILFONG A., DEVINSKY O., BLUVSTEIN J., MARSH E.D. et al. : Cannabidiol as a Potential Treatment for Febrile Infection-Related Epilepsy Syndrome (FIRES) in the Acute and Chronic Phases, Journal of Child Neurology, 2016.
  37. GROSS D.W., HAMM J., ASHWORTH N.L. et al. : Marijuana use and epilepsy : prevalence in patients of a tertiary care epilepsy center, Neurology, 200’, 62, 2095-2097.
  38. GUGGENHUBER S., MONORY K., LUTZ B., KLUGMANN M.M. : AAV vector-mediated overexpression of CB1 cannabinoid receptor un pyramidal neurons of the hippocampus protects against seizure-induced excitotoxicity, PloS One, 2010, 5, 12, 15707.
  39. GUY G., WRIGHT S., MEAD A., DEVINSKY O. : Use of Cannabinoids in the treatment of Epilepsy, 2015, Patent Application Pub : US 2016/0166515 A1, GW Pharma Limited, Cambridge, (GB), June 2016.
  40. HAUSMAN-KEDEM M., MENASCU S., KRAMER U. : Efficacy of CBD-enriched medical cannabis for treatment of refractory epilepsy in children and adolescents – An observational, longitudinal study, Brains & Development, 2018, in press.
  41. HEDGE M., SANTOS-SANCHEZ C., HESS P. et al. : Seizure exacerbation in two patients with focal epilepsy following marijuana cessation, Epilepsy & Behavior, 2012, 25, 4, 563-566.
  42. HILL A.J., HILL T.D.M., WHALLEY B.J. : The Development of Cannabinoid Based Therapies for Epilepsy, Molecular, Pharmalogical, Behavioral and Clinical Feature, 2013, 164-24.
  43. HUSSAIN S.A., ZHOU R., JACOBSON C. et al. : Perceived efficacy of cannabidiol-enriched cannabis extracts for treatment of pediatric epilepsy : A potential role for infantile spasms and Lennox-Gastaut syndrome, Epilepsy & Behaviour, 2015, 47, 138-141.
  44. JOHNSON D.D., McNEILL J.R., CRAWFORD R.D. et al. : Epileptiform seizures in domestic fowl. The anticonvulsant activity of delta 9-tetrahydrocannabinol, Can J Physiol Pharmacol, 1975, 53, 439-448.
  45. JONES et al. : Cannabidiol exerts anti-convulsant effects in animal models of temporal lobe and partial seizures, Seizures, 2012, 21, 5, 344-352.
  46. KALKACH-APARICIO M., CUELLAR-HERRERA M., FLORES-RAMIREZ E.L. et al. : The use of cannabis as an antiepileptic treatment in Mexico : A review, bioethical analysis, discussion and position of the Hospital General de Mexico, Epilepsy Clinic, Revista Médical del Hospital General de Mexico, 2016, 11 p.
  47. KAPLAN E.H., OFFERMANN E.A., SIEWERS J.W., COMI A.M. : Cannabidiol treatment for refractory seizures in Sturge-Weber syndrome, Pediatr Neurol, 2017, 71, 18-23.
  48. KARANIAN D.A., KARIM S.L., WOOD J.T., WILLIAMS J.S., et al. : Endocannabinoid enhancement protects against kainic acid-induced seizures and associated brain dammage, J Pharmacol Exp Ther, 2007, 322, 3, 1059-1066.
  49. KATONA I. : Cannabis and Endocannabinoid Signaling in Epilepsy, Handbook of Experimental Pharmacology, 2015, 231, 285-316.
  50. KOO C.M., KANG H.-C. : Could Cannabidiol be a Treatment Option for Intractable Childhood and Adolescent Epilepsy ?, Journal of Epilepsy Research, 2017, 7, 1, 1-5.
  51. KWAN P., ARZIMANOGLOU A., BERG A.T. et al. : Definition of drug resistant epilepsy : Consensus proposal by the ad hoc Task Force of the ILAE Commission on Therapeutic Strategies, Epilepsia, 2010, 51, 6, 1069-1077.
  52. LADINO L.D., HERANDEZ-RONQUILLO L., TELLEZ-ZENTENO J.F. : Medical marijuana for epilepsy : a case series, Can J Neurol Sci, 2014, 41, 753-758.
  53. LEO A., RUSSO E., ELIA M. : Cannabidiol and epilepsy : Rationale and therapeutic potential, Pharmacological Research, 2016, 107, 85-92.
  54. LIPPIELLO P., BALESTRINI S. CITRARO R., RUSSO E. et al. : From Cannabis to Cannabidiol to Treat Epilepsy, Where Are We, Curr Pharm Des, 2016, 22, 42, 6426-6433.
  55. LONGO D.L., FRIEDMAN D., DEVINSKY O. : Cannabinoids in the treatment of epilepsy, New England Journal of Medicine, 2015, 373 1048-1058.
  56. LORENZ R. : On the application of cannabis in paediatrics and epileptology, Neuroendocrinol Lett, 2004, 25, 1-2, 40-44.
  57. LUTZ B. : On-demand activation of the endocannabinoid system in the control of neuronal excitability and epileptiform seizures, Biochemical Pharmacology, 2004, 68, 1691-1698.
  58. MARSICANO G., GOODENOUGH S., MONORY K., HERMAN H. et al. : CB1 cannabinoid receptors and on-demand defense against excitotoxicity, Science, 2003, 302 (5642), 84-88.
  59. MARTIN A.R., CONSROE P., SINGH V., MECHOULAM R. et al. : Structure-anticonvulsant activity relationships of cannabidiol analogs, NIDA Research Monography, 1987, 79, 48-58.
  60. McLACHLAN R.S. : Marijuana : A Time-Honored but Untested Treatment for Epilepsy, Canadian Journal of Neurological Sciences, 2015, 42, 2, 88-91.
  61. MELDRUM B.S., FARIELLO R.G., PUIL E.A. et al. : Delta 9-tetrahydrocannabinol and epilepsy in the photosensitive baboon Papio papio, Epilepsia, 1974, 15, 255-264.
  62. MONORY K, MASSA F., EGERTOVA M., EDER M. et al. : The endocannabinoid system controls key epileptogenic circuits in the hippocampus, Neuron, 2006, 51, 4, 455-466.
  63. MORTATI K., DWORETZKY B., DEVINSKY O. : Marijuana : An Effective Antiepileptic Treatment in Partial Epilepsy ? A Case Report and Review of the Literature, Reviews in Neurological Diseases, 2007, 4, 2, 103-106.
  64. NAIDOO V., NIKAS S.P., KARANIAN D.A., WOOD J.T. et al. : A new generation fatty acid amide hydrolase inhibitor protects against kaiante-induced excitotoxicity, Journal of Molecular Neuroscience, 2011, 43, 3, 493-502.
  65. NAIDOO V., KARANIAN D.A., VADIVEL S.K., LOCKLEAR J.R. et al. : Equipotent inhibition of fatty acid amide hydrolase and monocylglycerol lipase – Dual targets of the endocannabinoid system to protects against seizure pathology, Neurotherapeutics, 2012.
  66. NEALE M. : Efficacy and safety of cannabis for treating children with refractory epilepsy, Nurs Child Young People, 2017, 29, 7, 32-37.
  67. O’CONNEL B.K., GLOSS D., DEVINSKY O. : Cannabinoids in treatment-resistant epilepsy : a review, Epilepsy & Behavior, 2016, 8 p.
  68. OHRI A., DOUGHERTY M. : Exploring the Use of Cannabidiol in Epilepsy Management, Practical Neurology, 2016, July/August, 48-50.
  69. OLDHAM M., SULLIVAN J., SINGHAL N., TILTON N., CILIO M. : Long-term efficacy and tolerability of add-on cannabidiol for drug-resistant pediatric epilepsie, in « Procedings of the American Epilepsy Society Annual Meeting, 2015, December 4-8, Philadelphia, P.A., Abstr 2.296, American Epilepsy Society, Chicago, Il.
  70. PATI S, ALEXOPOULOS A.V. : Pharmacoresistant epilepsy : From pathogenesis to current and emerging therapies, Cleveland Clinic Journal of Medicine, 2010, 77, 7, 457.
  71. PORTER B.E., JACOBSON C. : Report of a parent survey of cannabidiol-enriched cannabis use in pediatric treatment-resistant epilepsy, Epilepsy & Behavior, 2013, 29, 3, 574-577.
  72. PRESS C.A., KNUPP K.G., CHAPMAN K.E. : Parental reporting of response to oral cannabis extracts for treatment of refractory epilepsy, Epilepsy & Behavior, 2015, 45, 49-52.
  73. REDDY D.S., GOLUB V.M. : The Pharmacological Basis of Cannabis Therapy for Epilepsy, J Pharmacol Exp Ther, 2016, 357, 1, 45-55.
  74. REDDY D.S. : The Utility of Cannabidiol in the Treatment of Refractory Epilepsy, Clin Pharmacol Ther, 2017, 101, 2, 182-184.
  75. REGESTA G., TANGANELLI P. : Clinical aspects and biological bases of drug-resistant epilepsies, Epilepsy Research, 1999, 34, 2, 109-122.
  76. ROSENBERG E.C., TSIEN RW, WHALLEY B.J., DEVINSKY O. : Cannabinoids and Epilepsy, Neurotherapeutics, 2015, 18, 747-768. (Cochrane Review)
  77. ROSENBERG E.C., LOUIK J., CONWAY E., DEVINSKY O., FRIEDMAN D. : Quality of Life in Childhood Epilepsy in pediatric patients enrolled in a prospective, open-label clinical study with cannabidiol, Epilepsia, 2017, 1-5.
  78. RUSSO E.B. : Cannabis and epilepsy : An ancient traitement returns to the fore, Epilepsy & Behavior, 2016, 6 p.
  79. SAADE D., JOSHI C. : Pure cannabidiol in the treatment of malignant migrating partial seizures in infancy : a case report, Pediatr Neurol, 2015, 52, 5, 544-547.
  80. SURAEV A.S., TODD L., BOWEN M.T., ALLSOP D.J. et al. : An Australian nation wide survey on medicinal cannabis use for epilepsy : History of antiepileptic drug treatment predicts medicinal cannabis use, Epilepsy & Behavior, 2017, 7 p.
  81. SZAFLARSKI J.P., BEBIN E.M. : Cannabis, cannabidiol and epilepsy – From receptors to clinical response, Epilepsy & Behavior, 2014, 41, 277-282.
  82. SZAFLARSKI J.P., MARTINA BEBIN E., COMI A.M., PATEL A.D. et al. : Long-term safety and treatment effects of cannabidiol in children and adults with treatment-resistant epilepsies : Expanded access program results, Epilepsia, 2018, 1-9.
  83. SZAFLARSKI J.P., MARTINA BEBIN E., CUTTER G., DeWOLF J. et al. : Cannabidiol improves frequency and severity of seizures and reduces adverse events in an open-label add-on prospective study, Epilepsy & Behavior, 2018 Aug 9, pii: S1525-5050(18)30473-6. doi: 10.1016/j.yebeh.2018.07.020.
  84. TANG R., FANG F. : Trial of Cannabidiol for Drug –Resistant Seizures in the Dravet Syndrome, Comment, New England Journal of Medicine, 2017, 377, 7, 699.
  85. THIELE E.A., MARSH E.D., FRENCH J.A. et al. – GWPCARE4 Study Group : Cannabidiol in patients with seizures associated with Lennox-Gastaut syndrome (GWPCARE4) : a randomised, double-blind, placebo-controlled phase 3 trial, The Lancet,
  86. TREAT L., CHAPMAN K.E., COLBORN K.L., KNUPP K.G. : Duration of use of oral cannabis extract in a cohort of pediatric epilepsy patients, Epilepsia, 2017, 58, 1, 123-127.
  87. TREMBLY B., SHERMAN M. : Double –blind clinical study of cannabidiol as a secondary anticonvulsant, in « Marijuana’90 International Conference on Cannabis and Cannabinoids», 1990.
  88. TURKANIS S.A., SMILEY K.A., BORYS H.K., OLSEN D.M., KARLER R. : An electrophysiological analysis of the anticonvulsant action of cannabidiol on limbic seizures in conscious rats, Epilepsia, 1979, 20, 4, 351-363.
  89. TZADOK M., ULIEL-SIBONI S., LINDER I. et al. : CBD-enriched medical cannabis for intractable pediatric epilepsy : the current Israeli experience, Seizure, 2016, 35, 41-44.
  90. UPADHYA D., CASTRO O.W., UPADHYA R., SHETTY A.K. : Prospects of cannabidiol for easing Status Epilepticus-Induced Epileptogenesis and related Comorbidities, Molecular Neurobiology, 25 January 2018, doi.org/10.1007/s12035-018-0898-y.
  91. VEZYROGLOU K., CROSS J.H. : Targeted Treatment in Childhood Epilepsy Syndromes, Epilepsy, Current treatment Options Neurology, 2016, 18, 29, 12 pp.
  92. WADA J.A., OSAWA T., CORCORAN M.E. : Effects of tetrahydrocannabinols on kindled amygdaloid seizures and photogenic seizures in Senegalese baboons papio papio, Epilepsia, 1975, 16, 439-448.
  93. WALLACE M.J., BLAIRR.E., FALENSKI K.W., MARTIN B.R., DeLORENZO R.J. : The endogenous cannabinoid system regulates seizure frequency and duration in a model of temporal lobe epilepsy, J Pharm Exp Ther, 2003, 307, 129-137.
  94. WELTY et al. : Cannabidiol : promise and pitfalls, Epilepsy Curr, 2014, 14, 5, 250-252.
  95. WONG S.S., WILENS T.E. : Medical Cannabinoids in Children and Adolescents : A Systematic Review, Pediatric, 2017, 140, 16 p.

EPIDIOLEX® – Epilepsie de l’enfant

 

Essais cliniques : DEVINSKY et al. (2014), DEVINSKY et al. (2016), DEVINSKY et al. (2017).

GW Pharmaceutical, NCT02091375. (2015)

– Epidiolex® : 98 % CBD oil.

– Dose 25 à 50 mg/kg/jour.

 

  • DEVINSKY O., CILIO M.R., Di MARZO V., FRIEDMAN D. et al. : Cannabidiol : pharmacology and potential therapeutic role in epilepsy and other neuropsychiatric disorders, Epilepsia, 2014, 55, 6, 791-802.
  • DEVINSKY O., MARSH E., FILLOUX F., BLUVSTEIN J., CILIO M.R. et al. : Cannabidiol in patients with treatment-resistant epilepsy : an open-label interventional trial, Lancet Neurology, 2015.
  • DEVINSKY O., CROSS J.H., WRIGHT S. : Trial of Cannabidiol for Drug –Resistant Seizures in the Dravet Syndrome, New England Journal of Medicine, 2017, 376, 21, 2011-2020.
  • LONGO D.L., FRIEDMAN D., DEVINSKY O. : Cannabinoids in the treatment of epilepsy, New England Journal of Medicine, 2015, 373 1048-1058.
  • O’CONNEL B.K., GLOSS D., DEVINSKY O. : Cannabinoids in treatment-resistant epilepsy : a review, Epilepsy & Behavior, 2016, 8 p.
  • ROSENBERG E.C., LOUIK J., CONWAY E., DEVINSKY O., FRIEDMAN D. : Quality of Life in Childhood Epilepsy in pediatric patients enrolled in a prospective, open-label clinical study with cannabidiol, Epilepsia, 2017, 1-5.
  • TANG R., FANG F. : Trial of Cannabidiol for Drug –Resistant Seizures in the Dravet Syndrome, Comment, New England Journal of Medicine, 2017, 377, 7, 699.

 

 

  • GW Pharmaceuticals Initiate second Phase 3 Pivotal Study of Epidiolex (CBD) i Lennox Gastaut Syndrome. Press Release, June 11, 2015.

 

https://www.gwpharm.com/epilepsy-patients-caregivers/clinicians-researchers

https://www.cannabis-medicinale.fr/epidiolex/

  • GW Pharmaceuticals and the Government of New South Wales announce a strategic agreement to study epidiolex and CBDV in a clinical trial and research program for children with epilepsy, GW Pharma Press Release, October 17, 2015

http://www.gwpharm.com/GWPandGovNewSouthWales271015.aspx.

 

  • USA : Use of Cannabinoids in the treatment of Epilepsy, 2015, Patent Application Pub : US 2016/0166515 A1, GW Pharma Limited, Cambridge, (GB) : GUY G., WRIGHT S., MEAD A., DEVINSKY O. (June 2016)

 

Autres essais cliniques :

 

Essai clinique : TREMBLY B. et SHERMAN M. (1990)

  • « no differences between CBD and Placebo »
  • faible dose CBD (100 mg once daily)

 

  • TREMBLY et SHERMAN : Double –blind clinical study of cannabidiol as a secondary anticonvulsant, in « Marijuana’90 International Conference on Cannabis and Cannabinoids», 8-11 Juillet 1990, Kolymbari, Crète, IACM.

 

 

Essai clinique : Open study, Faculté de Médecine, Università « La Sapienza », 00100 Rome, Italy, (2002) :

  • CBD in a 2,5% corn oily

 

  • PELLICCIA A., GRASSI G., ROMANO A., CROCCHIALO P. : Treatment with CBD in oily solution of drug-resistant paediatric epilepsies, 2005 Congress on Cannabis and the Cannabinoids, Leiden, The Nederlands, Meeting Abstract, IACM, p 14.

 

 

Essai clinique : LORENZ (2004)

  • Dronabinol
  • Case series (Neurodegenerative diseases, mitochrondopathy, post-hypoxic state, epilepsy)

 

  • LORENZ R. : On the application of cannabis in paediatrics and epileptology, Neuroendocrinol Lett, 2004, 25, 1-2, 40-44.

 

 

Essai clinique : HESS et al. (2011)

– étude de l’efficacité du CBD dans le cadre des épilepsies résistantes dans la Sclérose Tubéreuse Complexe (TSC)

 

  • HEDGE M., SANTOS-SANCHEZ C., HESS P. et al. : Seizure exacerbation in two patients with focal epilepsy following marijuana cessation, Epilepsy & Behavior, 2012, 25, 4, 563-566.

 

 

Essai clinique : GEDDE et MAA (2013)

  • Realm Oil (extract of 16 :1 CBD cannabis plant)
  • 4 à 12 mg/kg /jour

 

 

Essai clinique : PORTER et JACOBSEN (2013) : étude faite par des parents d’enfants présentant des épilepsies résistantes et prenant régulièrement du cannabis

  • CBD-enriched cannabis product
  • 19 patients, 16 répondeurs

 

  • PORTER B.E., JACOBSON C. : Report of a parent survey of cannabidiol-enriched cannabis use in pediatric treatment-resistant epilepsy, Epilepsy & Behavior, 2013, 29, 3, 574-577.

 

 

Essai clinique : FRIEDMAN et al. (2014)

  • CBD (Epidiolex® 25 mg/kg / jour) + clobazam (17 patients) + group control clobazam (16 patients)
  • 7/17 patients on pu obtenir une réduction de leur dose de clobazam

 

  • FRIEDMAN D., CILIO M.R., TILTON N. et al. : The effects of Epidiolex (Cannabidiol) on serum levels of concomitant anti-epileptic drugs in children and young adults with treatment resistant epilepsy in an expand acess program, Annual Meeting of the American Epilepsy Society, Seattle, December 5-9, 2014, Abstract.

 

Essai clinique : SAADE et JOSHI (2015)

  • MMSI
  • CBD Case Report

 

  • SAADE D., JOSHI C. : Pure cannabidiol in the treatment of malignant migrating partial seizures in infancy : a case report, Pediatr Neurol, 2015, 52, 5, 544-547.

 

 

Essai clinique : HUSSAIN et al. (2015)

  • CBD-enriched OCE
  • Parent survey

 

  • HUSSAIN S.A., ZHOU R., JACOBSON C. et al. : Perceived efficacy of cannabidiol-enriched cannabis extracts for treatment of pediatric epilepsy : A potential role for infantile spasms and Lennox-Gastaut syndrome, Epilepsy & Behaviour, 2015, 47, 138-141.

 

 

Essai clinique : PRESS et al. (2015)

  • OCE
  • Retrospective chart review

 

  • PRESS C.A., KNUPP K.G., CHAPMAN K.E. : Parental reporting of response to oral cannabis extracts for treatment of refractory epilepsy, Epilepsy & Behavior, 2015, 45, 49-52.

 

 

Essai clinique : TZADOK et al. (2016)

  • CBD-enriched OCE
  • Retrospective chart review

 

  • TZADOK M., ULIEL-SIBONI S., LINDER I. et al. : CBD-enriched medical cannabis for intractable pediatric epilepsy : the current Israeli experience, Seizure, 2016, 35, 41-44.

 

 

Essai clinique : TREAT et al. (2017)

  • OCE
  • Retrospective chart review

 

  • TREAT L., CHAPMAN K.E., COLBORN K.L., KNUPP K.G. : Duration of use of oral cannabis extract in a cohort of pediatric epilepsy patients, Epilepsia, 2017, 58, 1, 123-127.

 

 

Essai clinique : KAPLAN et al. (2017)

  • CBD
  • Open-label trial

 

  • KAPLAN E.H., OFFERMANN E.A., SIEWERS J.W., COMI A.M. : Cannabidiol treatment for refractory seizures in Sturge-Weber syndrome, Pediatr Neurol, 2017, 71, 18-23.

 

 

Essai clinique : GOFSHTEYN et al. (2017)

  • CBD
  • Open-label trial

 

  • GOFSHTEYN J.S., WILFONG A., DEVINSKY O., BLUVSTEIN J., MARSH E.D. et al. : Cannabidiol as a Potential Treatment for Febrile Infection-Related Epilepsy Syndrome (FIRES) in the Acute and Chronic Phases, Journal of Child Neurology, 2016.

 

Pièces jointes

Laisser un commentaire

Votre adresse de messagerie ne sera pas publiée. Les champs obligatoires sont indiqués avec *